Yubero, Alfonso
Barquín, Aranzazu
Estévez, Purificación
Pajares, Bella
Sánchez, Luisa
Reche, Piedad
Alarcón, Jesús
Calzas, Julia
Gaba, Lydia
Fuentes, José
Santaballa, Ana
Salvador, Carmen
Manso, Luis
Herrero, Ana
Taus, Álvaro
Márquez, Raúl
Madani, Julia
Merino, María
Marquina, Gloria
Casado, Victoria
Constenla, Manuel
Gutiérrez, María
Dosil, Alba
González-Martín, Antonio
Funding for this research was provided by:
Clovis Oncology
Article History
Received: 10 June 2022
Accepted: 17 October 2022
First Online: 8 November 2022
Declarations
:
: The study protocol was approved by the ethics committee of HM Hospitales (Code: 20.05.1633-GHM) and performed according to the Declaration of Helsinki and local laws and regulations. Patients provided written informed consent. Informed consent was not required from inaccessible patients according to Spanish laws.
: Not applicable.
: AY: Consulting or advisory role: Clovis Oncology, GSK, AstraZeneca, MSD, PharmaMar, Roche. Travel, accommodation, expenses: MSD, GSK, PharmaMar.AB: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.PE: Consulting fees and honoraria for lectures, presentations, speaker bureaus: MSD, GSK, AstraZeneca, Clovis Oncology and PharmaMar.BP: Consulting or advisory role: Clovis Oncology, Novartis, AstraZeneca. Travel, accommodation: AstraZeneca.LS: Consulting or advisory role: GSK-Tesaro, Clovis Oncology, AstraZeneca, MSD, Roche. Travel, accommodation, expenses: GSK, MSD, PharmaMar.PR: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.JA: Consulting or advisory role: GSK, Clovis, AstraZeneca, MSD, Roche. Travel, accommodation, expenses: GSK, MSD, PharmaMar.JC: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.LG: Consulting fees and honoraria for lectures, presentations, speaker bureaus: MSD, GSK, AstraZeneca, Clovis Oncology and PharmaMar.JF: Advisory Board: Roche, AstraZeneca, Clovis Oncology and GSK.AS: Consulting fees and honoraria for lectures, presentations, speaker bureaus: MSD, GSK, AstraZeneca, Clovis Oncology, Pfizer, Lilly, Novartis.CS: Consulting or advisory role: PharmaMar. Travel, accommodation, expenses: GSK, MSD, Pfizer, AstraZeneca.LM: Consulting or advisory role: Roche/Genentech, AstraZeneca, Novartis, Pfizer, Tesaro, Eisai, Lilly, Clovis Oncology, Pierre Fabre, GlaxoSmithKline. Speakers’ Bureau: Roche/Genentech, Novartis, Pfizer, AstraZeneca, Lilly. Research Funding: Tesaro.AH: Principal investigator of clinical trials: AstraZeneca, Roche. Member of advisory boards: GSK. Personal fees: Clovis Oncology, GSK, MSD and PharmaMar.AT: Personal fees and non-financial support: Roche, BMS, MSD, GSK, AstraZeneca and Pfizer.RM: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.JM: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.MM: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.GM: Consulting fees and honoraria for lectures, presentations, speaker bureaus: Roche, PharmaMar, GSK/Tesaro, MSD, AstraZeneca, Clovis Oncology, Medicamenta, Lilly, Pfizer.VC: Consulting or advisory role: GSK, AstraZeneca, MSD, PharmaMar. Travel, accommodation, expenses: GSK, AstraZeneca, MSD, PharmaMar.MC: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.MG: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.AD: Employee and owner of stock and stock options in Clovis Oncology, Inc.AGM: Advisory/Consultancy: Alkermes, Amgen, AstraZeneca, Clovis Oncology, Genmab, GSK, ImmunoGen, Merck Sharp & Dohme, macrogenmics, Novartis, Oncoinvent, Pfizer/Merck, PharmaMar, Roche, Sotio, Sutro. Speaker Bureau: AstraZeneca, PharmaMar, Roche, GSK, Clovis Oncology. Research Grant/Funding: Roche, TESARO: A GSK Company. Travel/Accommodation/Expenses: AstraZeneca, PharmaMar, Roche, TESARO: A GSK Company.